NeoGenomics is trading at $15.65, down 4.28%, with no clear company-specific catalyst identified for the October 12 pre-market decline.
- The October 5 leadership succession announcement and preliminary third-quarter revenue update preceded the move; coverage tied the earlier reaction to the announcement, not this decline.
- Healthcare was reportedly higher pre-market, while major U.S. indices were mixed, offering no clear same-direction market explanation.
- Price history shows recent volatility, including a 13.72% drop on October 6.